The company's transition from self-restraint to medication f...
The company's transition from self-restraint to medication for weight loss is seen as a necessary evolution, but the competitive landscape and supply constraints for GLP-1 drugs could pose challenges. As Oprah exits the stock, investors are advised to exercise caution.
WeightWatchers Is Seeking to Turn Its Business Around by Adding Subscribers to Its Clinical Business, Which Prescribes Medications Such as Ozempic and Zepbound -- Heard on the Street -- WSJ
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
3241Followers
0Following
8006Visitors
Follow